- Home
- AMOD vs BLRX Comparison
AMOD vs BLRX Comparison
Compare AMOD & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMOD
- BLRX
- Stock Information
- Founded
- AMOD 2014
- BLRX 2003
- Country
- AMOD United States
- BLRX Israel
- Employees
- AMOD N/A
- BLRX N/A
- Industry
- AMOD
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- AMOD
- BLRX Health Care
- Exchange
- AMOD NYSE
- BLRX Nasdaq
- Market Cap
- AMOD 18.7M
- BLRX 15.3M
- IPO Year
- AMOD N/A
- BLRX 2011
- Fundamental
- Price
- AMOD $1.19
- BLRX $4.45
- Analyst Decision
- AMOD
- BLRX Strong Buy
- Analyst Count
- AMOD 0
- BLRX 2
- Target Price
- AMOD N/A
- BLRX $19.00
- AVG Volume (30 Days)
- AMOD 206.4K
- BLRX 2.1M
- Earning Date
- AMOD 08-15-2025
- BLRX 08-14-2025
- Dividend Yield
- AMOD N/A
- BLRX N/A
- EPS Growth
- AMOD N/A
- BLRX N/A
- EPS
- AMOD 0.12
- BLRX N/A
- Revenue
- AMOD N/A
- BLRX $22,340,000.00
- Revenue This Year
- AMOD N/A
- BLRX N/A
- Revenue Next Year
- AMOD N/A
- BLRX N/A
- P/E Ratio
- AMOD $9.93
- BLRX N/A
- Revenue Growth
- AMOD N/A
- BLRX 91.68
- 52 Week Low
- AMOD $1.01
- BLRX $2.30
- 52 Week High
- AMOD $13.49
- BLRX $35.60
- Technical
- Relative Strength Index (RSI)
- AMOD N/A
- BLRX 50.17
- Support Level
- AMOD N/A
- BLRX $3.79
- Resistance Level
- AMOD N/A
- BLRX $4.62
- Average True Range (ATR)
- AMOD 0.00
- BLRX 0.56
- MACD
- AMOD 0.00
- BLRX -0.13
- Stochastic Oscillator
- AMOD 0.00
- BLRX 21.79
About AMOD ALPHA MODUS HOLDINGS INC
Alpha Modus Holdings Inc is a technology company with a core focus on artificial intelligence in retail. It is engaged in creating, developing, and licensing data-driven technologies to enhance consumers' in-store digital experience at the point of decision.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.